Role of thiazolidinediones, insulin sensitizers, in non‐alcoholic fatty liver disease
Open Access
- 1 July 2013
- journal article
- review article
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 4 (6), 517-524
- https://doi.org/10.1111/jdi.12107
Abstract
The prevalence of metabolic syndrome, obesity and insulin resistance has become an epidemic in the world. A strong association exists between metabolic syndrome and non‐alcoholic fatty liver disease (NAFLD), though the etiology of NAFLD is still unclear. This close association leads to numerous clinical studies to investigate the effects of insulin sensitizers, thiazolidinediones (TZDs), on hepatic fat accumulation. Thiazolidinediones affect glucose and lipid metabolism in insulin‐sensitive tissues, which in turn reduces the lipid content in the liver by modulating several mediators. In the present review, we discuss key modulators – adiponectin and sirtulin‐adenosine monophosphate activated protein kinase signaling – as the mechanisms responsible for NAFLD related to metabolic syndrome.Keywords
Funding Information
- National Research Foundation of Korea (2012R1A1A2009143)
This publication has 95 references indexed in Scilit:
- A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitisJournal of Hepatology, 2011
- Systematic review: the diagnosis and staging of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitisAlimentary Pharmacology & Therapeutics, 2010
- Hepatic-Specific Disruption of SIRT6 in Mice Results in Fatty Liver Formation Due to Enhanced Glycolysis and Triglyceride SynthesisCell Metabolism, 2010
- A position statement on NAFLD/NASH based on the EASL 2009 special conferenceJournal of Hepatology, 2010
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic SteatohepatitisThe New England Journal of Medicine, 2010
- High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trialHepatology, 2010
- Diet and Exercise Interventions Reduce Intrahepatic Fat Content and Improve Insulin Sensitivity in Obese Older AdultsObesity, 2009
- Molecular Mechanisms of Lipotoxicity in Nonalcoholic Fatty Liver DiseaseSeminars in Liver Disease, 2008
- Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver diseaseNature Genetics, 2008
- Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying diseaseHepatology, 1999